As the cell and gene therapy (CGT) pipeline matures and new, exciting technologies scale into the clinic, the success of delivering the growing number of complex CGTs to patients in a safe and timely manner relies on robust and resilient global supply chains.

Join the 6th Supply Chain and Logistics for Cell and Gene Therapies Summit for the ultimate practical guide on designing and implementing scalable, traceable, and resilient global supply chains. For the first time, this forum will cover the full breadth of end-to-end supply chain challenges across both cell and gene therapy, bringing leading voices across autologous, allogeneic, in vivo, and ex vivo programs.

Leading clinical and commercial drug developers, trusted service providers, and expert clinical sites will lend solution-led case studies on securing resilient material supplies, implementing digital solutions, and ensuring seamless traceability of chain of identity and custody throughout the cold chain, enabling you to scale up, expand globally, and improve multistakeholder cross-collaboration.

We're uniting Supply Chain, Logistics, Sourcing, Quality, and Operations experts in the CGT industry, to share best practices in planning, sourcing, manufacturing, labeling, packaging, and delivery; and brainstorm practical solutions to the most pressing challenges in the field.

If you are laying out a design-and-execution plan for a scaled, integrated, end-to-end CGT supply chain - don't miss this unique opportunity to innovate and overcome the logistical challenges facing your program.

URLs:

Tickets: https://go.evvnt.com/2773127-2?pid=91 

Brochure: https://go.evvnt.com/2773127-3?pid=91 

Prices:

Drug Developer | Conference + Workshop Day: USD 4197.00,

Drug Developer | Conference Only: USD 2999.00,

Academic | Conference + Workshop Day: USD 3597.00,

Academic | Conference Only: USD 2599.00,

Standard | Conference + Workshop Day: USD 5097.00,

Standard | Conference Only: USD 3699.00

Speakers: Albert Ribickas, BMT Operations Manager, Moffitt Cancer Center, Aleh Bobr, Associate Professor, University of Nebraska Medical Center, Chris Baldwin, Vice President - Manufacturing and Supply, Resolution Therapeutics, Cristian Circiumaru, Director, Global Supply and External Manufacturing Planning, Orchard Therapeutics, Darcy Weyant, Associate Director, Clinical Supply, REGENXBIO, Jie Jia, Vice President, Strategic Alliances and Operations, CARsgen Therapeutics, Jorge Ryzwaniuk, Head of Supply Chain Management, Cell and Genes Therapies, Novartis, Joyce Chen, Director, Supply Chain, Legend Biotech, Karen Moniz, Technical Director, ICCBBA, Kellen LaVigne, Associate Director of Supply Chain, Aurion Biotech, Kevin Liao, Director - Supply Chain, Caribou Biosciences, Lizette Caballero, Associate Director, Clinical Cell Therapy Liaison, Johnson and Johnson Services, Robin Wilkinson, Deputy Technical Director, ICCBBA, Thomas Tredennick, Associate Director, Supply Chain, Arsenal Bio, Ute Brassat, Director, T-Knife Therapeutics, Vandana Sharma, Associate Director, Astellas Gene Therapies, Vishal Khanderia, Vice President, Supply Chain, Beam Therapeutics, William Shingler, Senior Director - Patient and Cell Management, Autolus